These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34093793)

  • 1. Regulatory region mutations of
    Xing X; Yuan X; Liu T; Dai M; Fan Y; Liu C; Strååt K; Björkholm M; Xu D
    J Cancer; 2021; 12(13):3853-3861. PubMed ID: 34093793
    [No Abstract]   [Full Text] [Related]  

  • 2. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of
    Jain M; Tivtikyan A; Kamalov D; Avdonin S; Rakhmatullin T; Pisarev E; Zvereva M; Samokhodskaya L; Kamalov A
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
    Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
    Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
    Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
    Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.
    Yuan X; Meng Y; Li P; Ge N; Kong F; Yang L; Björkholm M; Zhao S; Xu D
    Oncotarget; 2016 May; 7(22):31972-9. PubMed ID: 26934125
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Liu T; Li S; Xia C; Xu D
    Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
    Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
    J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of
    Garinet S; Pignot G; Vacher S; Le Goux C; Schnitzler A; Chemlali W; Sirab N; Barry Delongchamps N; Zerbib M; Sibony M; Allory Y; Damotte D; Bieche I
    Mol Cancer Res; 2019 Feb; 17(2):469-475. PubMed ID: 30401719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of molecular profiles of upper tract urothelial carcinoma
    Tomiyama E; Fujita K; Hashimoto M; Adomi S; Kawashima A; Minami T; Yoshimura K; Uemura H; Nonomura N
    Transl Androl Urol; 2022 Dec; 11(12):1747-1761. PubMed ID: 36632153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma.
    Xing X; Mu N; Yuan X; Wang N; Juhlin CC; Strååt K; Larsson C; Xu D
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32752127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
    Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
    Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
    Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
    Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.